Related Experiment Video

Updated: Aug 11, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Hypoparathyroidism and heart failure in thalassemic patients: a case report

Maria Tsironi1, Konstantinos Korovesis, Dimitris Farmakis

  • 1First Dept. of Internal Medicine, University of Athens, Medical School, Laiko Hospital, Ag. Thoma 17, 11527, Athens, Greece. gpoyl@otenet.gr

Pediatric Endocrinology Reviews : PER
|February 8, 2006
PubMed

Insights

Restoring normal calcium levels can effectively treat heart failure caused by hypoparathyroidism, even in complex cases like thalassemia. This finding highlights the importance of correcting hypocalcemia for cardiac function.

Area of Science:

  • Cardiology
  • Endocrinology
  • Hematology

Background:

  • Hypocalcemic cardiomyopathy, often linked to hypoparathyroidism, typically resists standard heart failure treatments.
  • Restoring normal calcium levels (normocalcemia) is crucial for managing this condition.

Observation:

  • A patient with thalassemia presented with severe cardiac failure.
  • Echocardiography revealed impaired biventricular function.
  • Laboratory tests indicated hypoparathyroidism secondary to hemosiderosis.

Findings:

  • The patient received treatment for both heart failure and calcium supplementation.
  • Significant clinical and laboratory improvements were observed after correcting hypocalcemia.
  • This case represents the first documented recovery from heart failure associated with hypoparathyroidism in a thalassemic patient following calcium correction.

Implications:

  • This study provides strong evidence for hypocalcemic cardiomyopathy as a treatable cause of heart failure.
  • Highlights the critical role of calcium balance in cardiac health, particularly in patients with chronic conditions like thalassemia.
  • Suggests routine screening for hypoparathyroidism and calcium levels in thalassemic patients with cardiac symptoms.

More Related Videos

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation07:13

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation

Published on: March 14, 2017

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...